Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163


Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD.

Science. 1997 Nov 21;278(5342):1447-50.


Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.

Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD.

J Virol. 1999 Aug;73(8):6715-20.


Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.

Feeney ME, Draenert R, Roosevelt KA, Pelton SI, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ.

J Immunol. 2003 Dec 15;171(12):6968-75.


HIV-specific immunity during structured antiviral drug treatment interruption.

Moss RB, Brandt C, Giermakowska WK, Savary JR, Theofan G, Zanetti M, Carlo DJ, Wallace MR.

Vaccine. 2003 Mar 7;21(11-12):1066-71.


HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia.

Koeppe JR, Campbell TB, Rapaport EL, Wilson CC.

J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):140-8.


Cellular immune response to human immunodeficiency virus.

Norris PJ, Rosenberg ES.

AIDS. 2001 Feb;15 Suppl 2:S16-21. Review.


Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

J Virol. 2003 May;77(10):6041-9.


Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.

Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF, Deeks SG.

AIDS. 2004 Apr 30;18(7):981-9.


Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection.

Malhotra U, Holte S, Zhu T, Delpit E, Huntsberry C, Sette A, Shankarappa R, Maenza J, Corey L, McElrath MJ.

J Virol. 2003 Feb;77(4):2663-74.


Characterization of HIV-1-specific T-helper cells in acute and chronic infection.

Rosenberg ES, LaRosa L, Flynn T, Robbins G, Walker BD.

Immunol Lett. 1999 Mar;66(1-3):89-93.


HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals.

Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA, Tsoukas CM, Lisziewicz J, Lori F.

J Immunol. 2008 May 1;180(9):5907-15.


Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.

Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, Gao F, Walker BD, Rosenberg ES.

J Immunol. 2003 Apr 1;170(7):3906-14.


HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.

Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, Sekaly RP.

J Exp Med. 2003 Dec 15;198(12):1909-22.


The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.

Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP.

J Infect Dis. 2000 Apr;181(4):1249-63. Epub 2000 Apr 13.


Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal.

Zheng NN, Kiviat NB, Sow PS, Hawes SE, Wilson A, Diallo-Agne H, Critchlow CW, Gottlieb GS, Musey L, McElrath MJ.

J Virol. 2004 Dec;78(24):13934-42.


Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.

Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, Baze W, Arlinghaus RB, Sastry KJ.

Vaccine. 2001 Dec 12;20(5-6):813-25.

Items per page

Supplemental Content

Write to the Help Desk